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Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by increased type I interferons (IFNs) and
multiorgan inﬂammation frequently targeting the skin. IFN-kappa is a type I IFN expressed in skin. A pooled genome-wide scan
implicated the IFNK locus in SLE susceptibility. We studied IFNK single nucleotide polymorphisms (SNPs) in 3982 SLE cases and
4275 controls, composed of European (EA), African-American (AA), and Asian ancestry. rs12553951C was associated with SLE
in EA males (odds ratio = 1.93, P = 2.5 × 10
−4), but not females. Suggestive associations with skin phenotypes in EA and AA
females were found, and these were also sex-speciﬁc. IFNK SNPs were associated with increased serum type I IFN in EA and AA
SLE patients. Our data suggest a sex-dependent association between IFNK SNPs and SLE and skin phenotypes. The serum IFN
association suggests that IFNK variants could inﬂuence type I IFN producing plasmacytoid dendritic cells in aﬀected skin.
1.Introduction
Systemic lupus erythematosus (SLE, OMIM 152700) is
an autoimmune disease characterized by production of
large quantities of antibodies directed against ubiquitous
self-antigens, particularly double-stranded DNA (dsDNA)
and small nuclear RNA-binding proteins such as Ro, La,
Sm, and nRNP. SLE is characterized by a striking 9:1
female to male diﬀerential in incidence [1], which remains
largely unexplained. Clinically, cutaneous manifestations
play a prominent role in SLE. The skin manifestations
which include discoid, malar, and photosensitive rashes, are
common and comprise 3 of the 11 American College of
Rheumatology (ACR) SLE classiﬁcation criteria [2, 3]. Cuta-
neous manifestations of SLE commonly precede diagnosis,
are among the initial manifestations of SLE in many, and
ultimately aﬀect the majority of patients [4–6].
Many recent studies have highlighted the role of the
type I interferon (IFN) pathway in SLE pathogenesis and
susceptibility [7, 8] .I n d e e d ,s e r u mI F N - a l p h a( I F N - α)
activity was shown to be a heritable risk factor for SLE [9],
and many genetic variants associated with SLE susceptibility
are associated with increased serum IFN-α activity in lupus
patients [10–13]. Additionally, age-related patterns of serum
IFN-α activity are present in both lupus patients and their
healthy family members which mirror peak SLE incidence
rates, with an earlier age of peak serum IFN-α in female
patients as compared to male patients [14]. Current models
of human SLE pathogenesis place plasmacytoid dendritic
cells in a central role, promoting type I IFN production,
which leads to the eventual loss of self-tolerance [reviewed
in [15]]. Increased production of type I IFN in SLE skin
lesions has been observed, and plasmacytoid dendritic cells
accumulate in cutaneous lupus lesions [16].
We performed a genome-wide study of 116,204 single
nucleotide polymorphisms (SNPs) in African-Americans
using a DNA pooling approach with the goal of identifying
general SLE susceptibility genes. Comparing 233 African
American SLE cases to 185 African American controls, we
found that the rs1031154 SNP 25,000 bp upstream of the
promoter for IFNK was associated with SLE (P<. 000007;
rank number 51 of 116,204 SNPs, Table 1). We did not
observe any additional associations in the type I IFN locus
or in the type III IFN locus.
The IFNK gene encodes the precursor for IFN-κ,a
recently discovered subclass of type I IFN [17]. IFN-κ is
a member of the type I IFN family, which in humans
consistsofIFN-α,IFN-β,IFN-ε,IFN-ω,andIFN-κ[18].This
family likely arose from gene duplication and diﬀerentiation
in mammals, and phylogenetically IFN-κ was the ﬁrst to
diverge, exhibiting 30% homology with other type I IFNs
[17,18].IFN-κ isa multifunctionaltype IIFNwhichinduces
autoimmunity when transgenically expressed in the β cells of
the pancreatic islets in mice [19]. IFN-κ is induced following
viral infection or treatment of cells with double-stranded
RNA [dsRNA] [17], and IFN-κ signaling induces a set of
genes(IRF1,STAT1,MXA,PKR,OAS1) commontosignaling
via the type I interferon receptor [17], and modulates the
release of cytokines from monocytes [20]. Unlike other
members of the type I IFN family, IFN-κ is constitutively and
highly expressed in keratinocytes [17].
Taken together, these data suggested inter-related
hypotheses of this study, that: [1] variation at the IFNK
locus confers susceptibility to SLE in humans, [2] the same
variation could modulate type I IFN levels in patients, and
[3]v a r i a t i o n sa ﬀecting the expression of IFN-κ in the skin
could alter the response to self-antigens in SLE skin and
predispose to cutaneous manifestations of SLE. Based on
this evidence and the clear biological plausibility of variation
near the promoter of a type I IFN gene as a risk factor for
SLE, we considered IFNK a possible candidate gene.
2. Methods
2.1. Genome-Wide Association Scan DNA Pooling Study.
Genomic DNA samples for 233 African-American (AA) SLE
patients and 185 AA controls were combined in pools strati-
ﬁed ﬁrst by case/control status and second by the presence or
absence of precipitating levels of autoantibodies against Sm
or nuclear riboncleoprotein (nRNP) complex autoantigens.
Equimolar amounts of DNA (as determined by Nanodrop
ND-1000 spectrophotometer [Nanodrop Wilmington, DE])
for each individual in a given pool were combined, which
thereafter was treated as a single sample until data analysis.
Each pooled sample was evaluated for case versus control
signal intensity diﬀerences for the SNPs included on the
Aﬀymetrix 100K Gene Chip Mapping Set arrays [Aﬀymetrix
Santa Clara, CA] according to manufacturer instructions.
SNP allele frequency estimates for each pool were calculated
using correction factors, as described in [21], and the
signiﬁcance of the diﬀerence between the average allele
frequencies between cases and controls was assessed by
performing an χ2 test with one degree of freedom on the z2
statistic as described [22] .A l ls u b j e c t si nt h i sg e n o m e - w i d e
study as well as those in the subsequent portions of the studyJournal of Biomedicine and Biotechnology 3
Table 1: Initial results for the IFNK region in the pooled genome-wide association study In African-American subjects.
Rank RS ID Position SLE Control P-Value (Z2)G e n e
10579 rs2069031 27417257 0.24 0.18 .084533 MOBKL2B
25111 rs763372 27418665 0.37 0.33 .233357 MOBKL2B
30738 rs1058326 27437089 0.64 0.67 .295482 MOBKL2B
96108 rs10511817 27444173 0.74 0.74 .991276 MOBKL2B
58144 rs1822724 27446580 0.18 0.20 .587242 MOBKL2B
86908 rs10511816 27458461 0.12 0.13 .892110 MOBKL2B
29622 rs7866248 27464593 0.66 0.62 .282786 MOBKL2B
51 rs1031154 27488800 0.58 0.74 .000007 MOBKL2B
83966 rs2783009 27504584 0.27 0.27 .860562 MOBKL2B
30667 rs774354 27505967 0.66 0.62 .294678 MOBKL2B
44987 rs774353 27506436 0.33 0.35 .445904 MOBKL2B
51264 rs10511815 27508821 0.10 0.08 .513456 MOBKL2B
3058 rs700795 27510508 0.21 0.29 .016545 MOBKL2B
3280 rs3849944 27550594 0.45 0.37 .018332 C9orf72
13896 rs7864840 27573468 0.21 0.17 .117979
96358 rs590299 27591570 0.28 0.28 .993607
85694 rs634157 27598585 0.80 0.80 .878910
Rank: rank order of association in the study, as determined by P-value, position is listed in base pairs on chromosome 9. “SLE” and “Control” indicate the
calculated allele frequencies in SLE patients and controls, respectively.
provided informed consent under the protocols approved by
the institutional review board at the respective institution.
2.2. Individual Genotyping and Population Deﬁnition in
LLAS1. Altogether 21 SNPs in the IFNK region on chromo-
some 9 between rs10812605 and rs3739526 were selected for
followup in this study. We did not include the exact SNPs
studied in the initial GWAS screening study described above
but instead studied SNPs which correlated with many other
SNPsinthelocus,andthereforetaggingalargeproportionof
the genetic variation within and near IFNK. The rs1838430
SNP was highly correlated with the rs1031154 SNP which
showed the strongest association in the GWAS study (r-
squared= 1.0 in EA, 0.59 in AA, and 0.66 in Asian subjects
according to the HapMap database). We studied these 21
taggingSNPsin12,043DNAsamplesusingcustom-designed
Illumina bead arrays as part of a larger candidate gene study
(Large Lupus Association Study 1 or LLAS1), which tested
19,354 SNPs for association with SLE susceptibility. The
quality control for this experiment is described elsewhere in
[23]. One SNP assay did not perform well enough for the
SNP to be called, and this SNP was not included in the study.
Two SNPs could not be automatically called by the Illumina
software, but genotype calls could be made clearly by
manually reviewing the genotype scatter plots (rs13691 and
rs13290599). The remaining SNPs were automatically called
by Illumina BeadStudio software [Illumina, Inc. San Diego,
CA] and manual inspection conﬁrmed clearly diﬀerentiated
genotype clusters. The overall call rate for automatically
called SNPs was 99.7%, and a single SNP, rs4609281, had a
call rate of 98%. Principal component analysis was used to
detect population substructure using all successfully called
nonrelated samples and SNPs from the larger study, and
population outliers were excluded from further analysis as
detailed in [23]. This resulted in 242 European ancestry (EA)
male cases and 931 controls, 2268 female EA cases and 2036
controls, 629 female African-American (AA) cases and 531
controls, 54 male AA cases and 252 controls, and 843 female
Asian cases and 777 Asian controls. Only 69 male Asian cases
and 90 male Asian controls were available, which would not
provide adequate power to detect even very large genetic
eﬀects, and these subjects were not analyzed as a subgroup.
All SLE patients met the American College of Rheumatology
(ACR) criteria for the diagnosis of SLE [2, 3]. The clinical
and serologic information for the SLE cases in each ancestral
background is shown in Table 2.
2.3. Data Analysis. Linkage disequilibrium (LD)
analysis was performed using Haploview 4.1 [24]
(http://www.broad.mit.edu/mpg/haploview), and diagrams
showing haplotype structures in each ancestral background
studied are shown in Figure 1. Minor allele frequency <0.05
w a su s e da sac u t o ﬀ in each population as well as P-value
for departure from Hardy-Weinberg equilibrium <.001
[23]. Association analysis was performed using the additive
genetic model as the primary inference using PLINK v1.07
[25]( http://pngu.mgh.harvard.edu/∼purcell/plink/)i n
each ancestral background and sex category separately.
Association analyses were performed as logistic regressions
using either SLE aﬀected versus unaﬀected or SLE
subphenotypes as outcome variables and the IFNK SNPs
as predictor variables. The ﬁrst four principal components
which were informative for ancestry as described above
[23] were incorporated as covariates in all association and4 Journal of Biomedicine and Biotechnology
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Figure 1: Haplotype diagrams showing LD structure between SNPs near the IFNK gene in each ancestral background. Generated using
Haploview 4.1 software, the plots show pairwise comparisons between each SNP in each ancestral background asr-squared values. Increased
dark shading indicates higher r-squared values between the two SNPs. Eur.European ancestry, Af-Am.African-American ancestry.Journal of Biomedicine and Biotechnology 5
Table 2: Clinical and serologic data for the SLE patients in each ancestral background.
African-American European Asian
No Yes Total No Yes Total No Yes Total
Renal 0.53 0.47 507 0.72 0.28 1069 0.54 0.46 674
Malar rash 0.63 0.37 508 0.44 0.56 1068 0.56 0.44 674
Discoid rash 0.76 0.24 508 0.89 0.11 1069 0.92 0.08 674
Photosensitivity 0.63 0.37 507 0.34 0.66 1069 0.66 0.34 674
Arthritis 0.24 0.76 508 0.18 0.82 1069 0.38 0.62 674
Oral ulcers 0.76 0.24 508 0.53 0.47 1069 0.62 0.38 674
Serositis 0.48 0.52 448 0.57 0.43 1025 0.72 0.28 673
Neurologic 0.87 0.13 508 0.89 0.11 1069 0.93 0.07 674
Hematologic 0.28 0.72 508 0.39 0.61 778 0.15 0.85 674
Immunologic 0.13 0.87 505 0.26 0.74 1064 0.00 1.00 674
ANA 0.01 0.99 508 0.03 0.97 1069 0.00 1.00 674
Anti-Ro 0.71 0.29 475 0.80 0.20 655 0.66 0.34 659
Anti-La 0.91 0.09 475 0.92 0.08 661 0.92 0.08 659
Anti-Sm 0.84 0.16 384 0.98 0.02 586 0.90 0.10 40
Anti-nRNP 0.62 0.38 384 0.92 0.08 586 0.65 0.35 40
Anti-Ribosomal P 0.98 0.02 384 0.99 0.01 586 0.95 0.05 40
“No” indicates the proportion of subjects lacking the clinical feature, and “Yes” is the proportion of subjects in whom that feature is present. Total indicates
the total number of subjects for whom data is available. The ﬁrst 11 rows are parameters assessed according to the American College of Rheumatology criteria
for SLE [2], while the ﬁve rows which begin with “Anti-” indicate particular SLE-associated autoantibody speciﬁcities. ANA: anti-nuclear antibody.
subphenotype analyses to control for potential confounding
relatedto population structure.SLEsubphenotypes analyzed
include the presence or absence of ACR clinical criteria for
skin (discoid rash, malar rash, or photosensitivity), high
versus low serum type I IFN activity deﬁned as 2SD above
healthy donors, as well as presence or absence of positive
autoantibody response as determined by positive reactivities
against dsDNA or select lupus-associated extractable nuclear
antigens. P-values shown are not corrected for multiple
comparisons. SNPs were screened for potential inﬂuence
on serum IFN by logistic regression as above, and then
quantitative serum IFN levels were plotted with respect
to the SNPs which showed evidence for association in EA
and AA, respectively. Two column nonparametric t-tests
were performed comparing serum IFN levels in major
allele homozygotes versus heterozygotes and minor allele
homozygotes combined in each sex in both ancestral
backgrounds.
Imputation analysis was performed using the GWAS
software suite (gtool, impute, and snptest, http://www
.stats.ox.ac.uk/%7Emarchini/software/gwas/gwas.html).
Untyped markers for EA and AA samples were imputed
using HapMap release number 22 CEU and YRI ﬁles,
respectively, and Asian samples were imputed using
HapMap release number 21 JPT+CHB combined ﬁles,
all obtained from the above website. SNPs were imputed
for the interval between 27485000bp and 27546000bp on
chromosome 9. Default values for conﬁdence score, buﬀer
size, and suggested values for founder population size were
used. Association analysis was performed as above, except
that the principal components of ancestry were not included
as covariates in the imputed analysis.
2.4. Measurement of Type I IFN in Serum and Analysis of
IFN Data. Serum type I IFN activity data were available
for 230 EA and 158 AA SLE patients in this study. The
reporter cell assay for type I IFN has been described in detail
elsewhere in [9, 26]. Reporter cells were used to measure the
ability of patient sera to cause IFN-induced gene expression.
The reporter cells (WISH cells, ATCC number CCL-25)
were cultured with 50% patient sera for 6 hours and then
lysed. mRNA was puriﬁed from cell lysates, and cDNA was
made from total cellular mRNA. cDNA was then quantiﬁed
using real-time PCR using an Applied Biosystems 7900HT
PCR machine with the SYBR Green ﬂuorophore system.
Forward and reverse primers for the genes MX1, PKR,
and IFIT1, which are known to be highly and speciﬁcally
induced by IFN-α, were used in the reaction [9]. GAPDH
was ampliﬁed in the same samples to control for background
gene expression. The amount of PCR product of the IFN-
induced gene was normalized to the amount of product
for the housekeeping gene GAPDH in the same sample.
The relative expression of each of the three tested IFN-
induced genes was calculated as a fold increase compared
to its expression in WISH cells cultured with media alone.
Results from the IFN assay were standardized to a healthy
multiancestral reference population as previously described,
and a serum IFN activity score was calculated based upon
the mean and SD of the reference population [9]. This assay
could theoretically measure all type I IFNs present in the
sample being studied. In SLE sera, type I IFN activity is
generally completely blocked by the addition of anti-IFN-
α antibodies [9, 26]. Thus, the activity observed in the
assay is frequently referred to as serum IFN-α activity. With
regard to potential cross-reactivity with the type III IFNs,6 Journal of Biomedicine and Biotechnology
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Figure 2: Stimulation of WISH reporter cells with IFN-α,I F N - κ,
and SLE sera with and without anti-IFN-κ antibodies. WISH cells
were assayed for type I IFN-induced gene expression as described in
the methods, using the stimuli indicated on the graph. Anti-IFN-κ
antibody was used at a concentration of 10μg/mL, and anti-IFN-κ
treated sera were preincubated with the antibody for 30 minutes
before the sera was applied to the WISH cells. Y-axis shows the
IFN-induced gene expression score calculated as described in the
Methods.
preincubation of SLE sera with anti-IFN λ1 antibodies did
not diminish the capacity of those sera to cause IFN-induced
gene expression in the reporter assay [26]. Given that IFN-
κ is a type I IFN, we clariﬁed the issue of whether our
reporter assay was detecting circulating IFN-κ in lupus sera.
Similar to published reports [17], we ﬁnd that recombinant
IFN-κ is capable of inducing some type I IFN-induced
gene expression in our reporter assay although this is much
less than that induced by the same amount of IFN-α
(Figure 2). When lupus sera with high type I IFN activity are
preincubated with anti-IFN-κ antibody, there is no decrease
in the observed type I IFN activity, supporting the idea that
IFN-κ does not contribute to circulating type I IFN activity
in SLE sera (Figure 2).
3. Results
3.1. rs12553951 C Is Associated with SLE in European Ances-
try Males. When each ancestral background was analyzed
separately in case-control analysis, there were no strong
associations observed (Table 3). Given the precedent for sex
diﬀerences in the association of type I IFN-pathway genes
[13, 27], we also analyzed females and males separately in
each background (Table 4). Surprisingly, there was evidence
for association between the rs12553951 C allele and SLE in
EA males [odds ratio (OR)= 1.93, 95% conﬁdence inter-
val (95%CI)= 1.36–2.74, P =2.5×10−4], but no similar
association in EA females. This association would withstand
statisticalcorrectionformultiplehypothesistesting,suchasa
Bonferroni correction for the number of SNPs tested within
the IFNK locus in this study (P-values <2.6×10−2 would
remain signiﬁcant after this correction). This correction
for multiple hypothesis testing is likely too conservative,
as independence between the individual measurements is
an assumption of this correction, and in fact many of the
SNPs tested in this study showed some degree of correlation
with other SNPs, as shown in Figure 1. The low number
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Figure 3: Association analysis of imputed IFNK SNPs. Each
symbol represents an SNP, with downward pointing triangles
showingtheSNPsdirectlygenotypedandupwardpointingtriangles
indicating the SNPs which were imputed (see methods for details of
imputation). Y-axis shows the inverse log of the P value resulting
from the case-control chi-square test statistic for each SNP. X-axis
shows the location of each SNP in bases along chromosome 9. Each
color represents a diﬀerent ancestral background/sex included in
this analysis. Due to low numbers, African-American (AA) males
and Asian males were not included. EA: European ancestry, M:
male, and F: female.
of male subjects tested relates to the low incidence of SLE
in males and reduces our conﬁdence to some degree that
this will prove to be a robust association to independent
replication. However, the observed OR of >1.9 is large for
human complex diseases, and genotyping of an independent
cohort in an eﬀort to deﬁnitively conﬁrm this association
would be warranted. No signiﬁcant eﬀect was observed
upon the case-control associations when age was used as a
covariate or when analyzing cases separated into age strata
as described in the study of the IFN pathway gene SPP1 in
[13]. We also imputed SNPs using the IMPUTE program
in the Genome-Wide Association Study Software suite by
Marchini et al. Using this algorithm we did not observe any
additional signiﬁcant associations with the imputed SNPs
which would exceed a Bonferroni correction for the number
of SNPs genotyped in the study (Figure 3).
3.2. IFNK SNPs Are Associated with Skin Phenotypes in
SLE. We next tested for associations between IFNK SNPs
and skin phenotypes in a case-case analysis of the SLE
patients. In female EA and AA SLE patients, seven SNPs
demonstrated evidence for association with discoid rash and
malar rash, respectively (Tables 5(a) and 5(b), resp.). More
than one SNP showed at least nominal (P<. 05) evidence
for association, however, conditioning on the strongest
association in each background abolished the marginal
signiﬁcance observed at the other SNPs (Tables 5(a) andJournal of Biomedicine and Biotechnology 7
Table 3: Additive model association results from IFNK locus in each ancestral background.
SNP MA European African-Americans Asians
Case Cont OR P Case Cont OR P Case Cont OR P
rs10967964 A 0.112 0.111 1.01 .88 0.022 0.025 0.85 .52 0.201 0.219 0.95 .50
rs1838430 C 0.037 0.042 0.87 .16 0.319 0.299 1.09 .27 — — — —
rs1977661 A 0.099 0.114 0.85 .010 0.136 0.124 1.13 .29 0.307 0.318 0.99 .88
rs10812605 G 0.352 0.351 1.00 .93 0.411 0.393 1.08 .32 0.395 0.402 0.95 .50
rs12553951 C 0.077 0.068 1.15 .06 0.016 0.009 1.79 .09 — — — —
rs4609281 C 0.277 0.282 0.98 .57 0.483 0.462 1.09 .25 0.237 0.200 1.17 .06
rs11792285 A 0.376 0.365 1.05 .24 0.098 0.100 0.98 .89 0.287 0.295 0.98 .76
rs13290599 A 0.069 0.066 1.05 .54 0.056 0.056 1.01 .93 0.118 0.138 0.85 .10
rs4879541 A 0.488 0.486 1.01 .87 0.165 0.166 1.01 .94 0.354 0.331 1.05 .50
rs2814707 A 0.237 0.232 1.03 .54 0.196 0.233 0.80 .014 0.059 0.043 1.27 .13
rs7469146 A 0.490 0.488 1.01 .83 0.120 0.126 0.96 .71 0.357 0.339 1.03 .73
rs10812611 G 0.466 0.466 1.00 .97 0.127 0.134 0.95 .64 0.357 0.337 1.03 .65
rs3861016 C 0.066 0.076 0.85 .038 — — — — 0.156 0.147 1.09 .39
rs17769217 C 0.127 0.128 0.99 .93 0.041 0.031 1.32 .18 — — — —
rs10967977 G 0.201 0.190 1.07 .15 0.028 0.037 0.77 .22 0.193 0.202 0.97 .76
rs13691 A 0.268 0.258 1.05 .27 0.079 0.080 1.02 .89 0.445 0.435 1.00 .98
rs12349820 G 0.236 0.232 1.02 .64 0.137 0.147 0.91 .40 0.109 0.096 1.09 .44
rs12686452 G 0.243 0.246 0.98 .61 0.138 0.126 1.12 .30 0.272 0.284 0.94 .42
MA: minor allele, “Case” and “Cont”: allele frequency of the minor allele in cases and controls, respectively, OR: odds ratio, P =P value.
Table 4: SNPs in the IFNK locus which demonstrate evidence for association with SLE following stratiﬁcation by sex in each ancestral
background.
SNP (ancestry) MA Females Males
Cases Cont OR (95% CI) P Cases Cont OR (95% CI) P
rs1977661 (EA) A 0.101 0.117 0.85 (0.74–0.98) .023 0.080 0.109 0.69 (0.48–0.99) .047
rs12553951 (EA) C 0.074 0.072 1.04 (0.88–1.23) .62 0.107 0.060 1.93 (1.36–2.74) .00025
rs3861016 (EA) C 0.067 0.078 0.85 (0.72–1.00) .05 0.056 0.071 0.75 (0.49–1.16) .20
rs2814707 (AA) A 0.195 0.235 0.79 (0.65–0.96) .020 0.204 0.229 0.85 (0.51–1.40) .52
EA: European ancestry, AA: African-American ancestry, MA: minor allele, “Case” and “Cont”: allele frequency of the minor allele in cases and controls
respectively, OR: odds ratio, 95% CI=95% conﬁdence interval of the odds ratio, P =P value.
5(b)).Interestingly,theallelefrequenciesofthemoststrongly
associatedSNPineachbackgroundinmalesshowedastrong
trend toward an opposite association as compared to that
found in females (Table 5(c)). Thus, the allele associated
with a skin phenotype in female patients shows evidence
of being protective against the same skin phenotype in
males of the same ancestral background. The low number
of males limits the statistical strength of these ﬁndings
although these preliminary allele frequency diﬀerences are
of large magnitude, and this parallel sex-skewing of genetic
associations with skin phenotypes in two diﬀerent ancestral
backgrounds is intriguing. Photosensitivity was not associ-
ated with IFNK SNPs, and no associations were observed
with SLE-associated antibodies (data not shown).
3.3. Serum Type I IFN Levels Are Related to IFNK SNPs in EA
and AA SLE Patients. We next analyzed serum type I IFN
activity in subjects with data available for this phenotype,
which included 230 European-American and 158 African-
American SLE patients. We ﬁrst used logistic regression
models with ancestry covariates to detect associations with
high serum type I IFN activity as a categorical trait (high
IFN was deﬁned as >2SD above healthy controls). In both
EA and AA, there was a single SNP associated with high
serum type I IFN activity in female patients. The rs12686452
A allele was associated with high serum IFN in EA females
(OR=2.79, 95% CI=1.48–5.29, P =1.6×10−3) and the
rs2814707 G allele was associated with high serum IFN in
AA females (OR=2.69, 95% CI=1.30–5.56, P =7.6×10−3).
Quantitative serum type I IFN activity in each ancestral
background stratiﬁed by SNP genotype is shown in Figure 4.
4. Discussion
In this study we analyzed the role of genetic variation
near the IFNK locus in SLE susceptibility and the clinical8 Journal of Biomedicine and Biotechnology
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Figure 4: Serum type I IFN levels in SLE patients stratiﬁed by IFNK genotype. Serum type I IFN activity in European (a) and African-
American (b) ancestry SLE patients is shown, stratiﬁed by genotype at the associated SNP in each ancestral background. Minor allele
homozygotes are combined with the heterozygous state in each case due to low numbers. Serum type I IFN activity is reported in relative
units (see methods for derivation of IFN activity). Data are nonnormally distributed, so the box-and-whiskers format is used, with lines
indicating the median, boxes showing the interquartile range, and error bars showing the 10th and 90th percentiles. P values were calculated
using a nonparametric Mann-Whitney U test.
Table 5: Markers suggestive of association with skin-related clinical criteria. “Conditioned on ...”=results from conditional logistic
regression performed conditioning on the indicated SNP, MA: minor allele, “Case” and “Cont”: allele frequency of the minor allele in cases
and controls respectively, OR: odds ratio, 95% CI=95% conﬁdence interval of the odds ratio, P:P value, AA: African-American ancestry,
EA: European ancestry, Female −: female subjects lacking the indicated skin phenotype, Female +: female subjects with the indicated skin
phenotype, Male −: males lacking the indicated skin phenotype, Male +: males with the indicated skin phenotype, Female ORs: odds ratio
comparing female patients with and without the indicated skin phenotype, and Male OR: odds ratio comparing male patients with and
without the indicated skin phenotype.
(a) AA female malar rash.
SNP MA OR (95% CI) P Conditioned on rs4879541
OR P
rs4609281 C 1.35 (1.03–1.78) .030 1.28 .091
rs11792285 A 0.60 (0.37–0.98) .043 0.92 .81
rs4879541 G 0.58 (0.39–0.85) .0061 ——
rs7469146 A 0.57 (0.36–0.89) .015 0.84 .66
rs10812611 A 0.57 (0.36–0.89) .014 0.80 .56
(b) EA female discoid rash.
SNP MA OR (95% CI) P Conditioned on rs2814707
OR P
rs4609281 C 1.47 (1.08–1.98) .013 1.04 .91
rs2814707 A 1.55 (1.13–2.12) .0063 ——
rs12686452 G 0.65 (0.45–0.94) .023 .73 .11
(c) Evidence for opposing associations with skin phenotypes in female and male subjects.
SNP Allele Female − Female + Male − Male + Female OR Male OR Phenotype
rs4879541 (AA) G 0.192 0.124 0.048 0.447 0.58 6.36 Malar
rs2814707 (EA) A 0.220 0.312 0.281 0.156 1.55 0.45 DiscoidJournal of Biomedicine and Biotechnology 9
expression of cutaneous and autoantibody manifestations of
SLE. While evidence supporting a genetic association was
observed in EA males with SLE, EA females with discoid
rash, AA females with malar rash, and EA and AA females
with serum type I IFN activity, the speciﬁc associated SNPs
were not the same for each phenotype and were not shared
across the diﬀerent ancestral backgrounds examined in this
study. This could be due to spurious association, although
there are other potential explanations as well. It is possible
that the associations we observe are due to linkage between
the marker SNPs we have genotyped and one or more as
yet unknown causal genetic variants in the IFNK locus.
Further examination of this locus with ﬁne mapping and
sequencing in multiple ancestral backgrounds will help to
answer this question. Also, it is possible that the causal
variant may be in the Mps One Binder kinase activator-like
2B (MOBKL2B) gene, which is also within this locus on
the opposite strand from IFNK (Figure 1). The MOBKL2B
gene is homologous to the yeast MOB1 gene, which is
involved in regulating mitotic spindle checkpoints, and it
seems that IFNK is a more likely candidate gene in this locus
given our current understanding of the biology of these two
genes.
Despite the diﬀerences we observe in genetic associations
between diﬀerent ancestral backgrounds, it is still possible
that the causal genetic elements are the same in all ancestral
backgrounds, and the diﬀerences in associations we observe
could relate to diﬀerent chromosomal linkage patterns
between the SNPs we genotyped and untyped causal variants
in diﬀerent backgrounds. Alternatively, it is possible that
diﬀerent causal variants in the IFNK locus are present in
diﬀerent ancestral backgrounds and predispose subjects to
diﬀerent subphenotypes. There is some precedent for this
phenomenon with SLE-risk loci [11, 13, 28].
If the association between rs12553951 C and SLE in
EA males is conﬁrmed in independent cohorts, this may
provide greater insight into the pathogenesis of male SLE,
which is not well understood at present. Interestingly, we
have previously observed evidence for sex-diﬀerences in
genetic associations in another type I IFN pathway gene,
osteopontin (SPP1)[ 13, 27]. In the largest study of SPP1
to date, an association of the previously reported risk allele
w a so n l yo b s e r v e di nm a l eS L Ep a t i e n t s[ 27]. This was
surprising, as males represented approximately 10% of the
population studied, similar to most studies of SLE. Another
study recently described sex-related diﬀerences in associa-
tions between the same risk variant of SPP1 and serum
cytokine patterns, which may provide some explanation
of the observations in previous studies in [13]. In this
study of SPP1, young female SLE patients were enriched for
the risk allele of SPP1 and demonstrated increased serum
osteopontin and type I IFN levels related to the risk variant,
while older female patients did not. Male patients, while
few in number, demonstrated a robust pattern of increased
serum cytokines related to the SPP1 risk allele, similar to the
younger female patients [13]. Given these data, we explored
ageasavariableinthisstudyalthoughthisdidnotresolvethe
diﬀerences in IFNK associations we observed between males
and females.
The potential associations of SNPs in the IFNK locus
with skin phenotypes in SLE is interesting, as IFN-κ is
expressed in the skin [17] and could conceivably play a role
in the skin inﬂammation characteristic of the SLE disease
process.Thesex-skewingofallelefrequenciesobservedinthe
associatedSNPsinrelationtoskinphenotypesisstrikingand
also warrants further validation in a greater number of male
subjects. While the reasons underlying the sex-diﬀerences
in association we observe at the IFNK locus are not clear,
the type I IFN system is crucial for placental reproduction
[29]. Additionally, the type I IFN gene family has diversiﬁed
extensively in placental mammals [18]. It is possible that sex
diﬀerences in the regulation of type I IFNs could relate to the
diﬀerences in associations we observe between disease states
a n ds o m et y p eII F Np a t h w a yg e n e s[ 30, 31].
If variants in the IFNK locus do not truly confer
susceptibility or alter the clinical expression of its various
manifestations, IFNK may yet play an important role in SLE
via modulation of serum type I IFN and other cytokines.
In this study we observe evidence for associations between
IFNK SNPsandserumtypeIIFNactivity.WeshowthatIFN-
κdoesnotcontributedirectlytotheserumtypeIIFNactivity
being measured, consistent with previous observations that
IFN-α has been the predominant type I IFN inducing the
serum activity observed in SLE patients [9, 26]. Alternatively,
it is possible that IFN-κ could exert an inﬂuence upon serum
type I IFN levels by acting locally in the skin. In this regard,
it has been noted that IFN-κ can bind strongly to heparin,
which would facilitate retention of the cytokine close to
the site of production in the skin [20]. The major IFN-α
producing cells are plasmacytoid dendritic cells. These cells
are frequently found SLE-aﬀected skin [16], and it seems
possible that IFN-κ could be involved in activating and
“priming” these cells. This type of feed-forward mechanism
has been described with other type I IFNs [32], and could
potentially explain an association of the IFNK locus with
s e r u ml e v e l so ft y p eII F N ,e v e ni ft h et y p eII F Nb e i n g
measured in serum is predominantly IFN-α.
A recent genome-wide association scan of diﬀerential
response to anti-tumor necrosis factor alpha (TNF-α)t r e a t -
ment in rheumatoid arthritis showed strong preliminary
evidence of association of a number of SNPs in the IFNK
locus with response or nonresponse to anti-TNF-α therapy
(ORs range from 4.9 to 5.4, P-values in the 4-5×10−4
range) [33]. Cross-regulation of type I IFN and TNF-α
has been observed in SLE [12] and other conditions [34],
and treatment with anti-TNF-α agents has been shown to
i n c r e a s es e r u mt yp eII F Na c t i v i t y[ 35]. Upregulation of type
I IFNs is one mechanism proposed for lack of response to
anti-TNF-α agents [36], and it is possible that IFNK variants
could contribute to dysregulation of the type I IFN pathway
in the setting of TNF-α inhibition. Anti-IFN-α therapy has
showed promise in recent trials in [37], as having therapies
modulating B-cell activating factor (BAFF) [38]. Indeed,
studies suggest that type I IFN exposure upregulates BAFF in
humans [35, 39], further supporting the idea that type I IFN
is related to a number of important pathological cytokines
in human disease. These data taken together suggest that
IFNK variants could play an important role in cytokine10 Journal of Biomedicine and Biotechnology
regulation in SLE and consequently the pharmacogenetics of
anti-cytokine therapies, even if a role for IFNK variants in
SLE susceptibility is not conﬁrmed.
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